Results 191 to 200 of about 1,365,887 (339)

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

open access: yesMolecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon   +4 more
wiley   +1 more source

Hepatectomy in children. [PDF]

open access: yes, 1982
Iwatsuki, S, Starzl, TE
core  

Multiple primary neoplasms of the lung

open access: yesThe Journal of Thoracic and Cardiovascular Surgery, 1968
S W, Leafstedt   +3 more
openaire   +2 more sources

Multiple primary malignant neoplasms in patients with esophageal cancer.

open access: yesDiseases of the esophagus, 2000
S. Nagasawa   +4 more
semanticscholar   +1 more source

Lactoferrin treatment activates acetylcholinesterase, decreasing acetylcholine levels in non‐small cell lung cancer (NSCLC) cell culture supernatants, inhibiting cell survival

open access: yesFEBS Open Bio, EarlyView.
Representation of the suggested mode of action of lactoferrin (Lf) in nonsmall cell lung cancer (NSCLC) A549 cells. Lf induces activation of caspase‐3 by activating p53 and AChE leading to decreased ACh concentrations. In turn, ACh signaling leads to activation of VEGF and AKT and blocking of caspase‐3.
Stuti Goel   +9 more
wiley   +1 more source

Multiple Primary Malignant Neoplasms: Case Report and a Comprehensive Review of the Literature

open access: yesAmerican Journal of Clinical Oncology, 2003
Carlo G N Demandante   +2 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy